Notch-associated MicroRNAs in cancer

Current Drug Targets

Volumn 14, Issue 10, 2013, Pages 1157-1166

  Mo, Yin Yuan ^a   Tang, Hua ^a,b   Miele, Lucio ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Gene silencing; MicroRNAs; Notch signaling; Tumorigenesis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADAM10 ENDOPEPTIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA SECRETASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 122; MICRORNA 144; MICRORNA 150; MICRORNA 181C; MICRORNA 199B; MICRORNA 200; MICRORNA 29; MICRORNA 34; MICRORNA 34A; MICRORNA 34C; MICRORNA 524; MYC PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; WNT1 PROTEIN; WNT4 PROTEIN;

APOPTOSIS; BREAST CARCINOMA; CANCER STEM CELL; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; HUMAN; NEOPLASM; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84881334111     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990188     Document Type: Review

References (107)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776.
2. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004; 9: 145-63.
3. Shi W, Harris AL. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 2006; 11: 41-52.
4. Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H. The Notch pathway in cancer: differentiation gone awry. Eur J Cancer 2005; 41: 2620-9.
5. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107: 2223-33.
6. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003; 3: 756-67.
7. Miele L. Notch signaling. Clin Cancer Res 2006; 12: 1074-9.
8. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-33.
9. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997; 90: 281-91.
10. Logeat F, Bessia C, Brou C, et al. The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci USA 1998; 95: 8108-12.
11. Fleming RJ. Structural conservation of Notch receptors and ligands. Semin Cell Dev Biol 1998; 9: 599-607.
12. Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrinmetalloprotease TACE. Mol Cell 2000; 5: 207-16.
13. Mumm JS, Schroeter EH, Saxena MT, et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 2000; 5: 197-206.
14. Hsieh JJ, Zhou S, Chen L, Young DB, Hayward SD. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci USA 1999; 96: 23-8.
15. Jarriault S, Brou C, Logeat F, et al. Signalling downstream of activated mammalian Notch. Nature 1995; 377: 355-8.
16. Kao HY, Ordentlich P, Koyano-Nakagawa N, et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998; 12: 2269-77.
17. Wu L, Griffin JD. Modulation of Notch signaling by mastermindlike (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol 2004; 14: 348-56.
18. Wu L, Aster JC, Blacklow SC, et al. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet 2000; 26: 484-9.
19. Wu L, Sun T, Kobayashi K, Gao P, Griffin J D. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002; 22: 7688-700.
20. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003; 194: 237-55.
21. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Over expression of the Notch1 intracellular domain (NICD) inhibits cellular proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006.
22. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001; 21: 5925-34.
23. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096-109.
24. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998; 18: 2077-88.
25. Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999; 18: 5973-81.
26. Chen Y, Fischer WH, Gill GN. Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. J Biol Chem 1997; 272: 14110-4.
27. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-5.
28. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008; 455: 1124-8.
29. Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 2010; 463(7281): 621-6.
30. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 2008; 105: 1608-13.
31. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol 2005; 3: e85.
32. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
33. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-33.
34. O'Donnell KA, Wentzel EA, Zeller KI, Dang C V, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-43.
35. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 2006; 12: 2014-24.
36. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67: 11099-101.
37. Wang Z, Li Y, Kong D, et al. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 2010; 292: 141-8.
38. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-43.
39. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-81.
40. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. Rna 2008; 14: 1539-49.
41. Piskounova E, Viswanathan SR, Janas M, et al. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem 2008; 283: 21310-4.
42. Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stemcell commitment. Nat Cell Biol 2008; 10: 987-93.
43. Viswanathan S R, Daley G Q, Gregory R I. Selective blockade of microRNA processing by Lin28. Science 2008; 320: 97-100.
44. Hobert O. miRNAs play a tune. Cell 2007; 131: 22-4.
45. Fragoso R, Mao T, Wang S, et al. Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1/b-1. PLoS Genet 2012; 8: e1002855.
46. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11: 252-63.
47. Brabletz S, Bajdak K, Meidhof S, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011; 30: 770-82.
48. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17: 7-30.
49. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-27.
50. Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-82.
51. Li H, Solomon E, Duhachek Muggy S, Sun D, Zolkiewska A. Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29. J Biol Chem 2011; 286: 21500-10.
52. Ishitani T, Hirao T, Suzuki M, et al. Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. Nat Cell Biol 2010; 12: 278-85.
53. Cichocki F, Felices M, McCullar V, et al. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J Immunol 2011; 187: 6171-5.
54. McGill MA, Dho SE, Weinmaster G, McGlade CJ. Numb regulates post-endocytic trafficking and degradation of Notch1. J Biol Chem 2009; 284: 26427-38.
55. McGill MA, McGlade CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem 2003; 278: 23196-203.
56. Fineberg SK, Datta P, Stein CS, Davidson BL. MiR-34a represses Numbl in murine neural progenitor cells and antagonizes neuronal differentiation. PloS one 2012; 7: e38562.
57. Mavrakis KJ, Wolfe AL, Oricchio E, et al. Genome-wide RNAmediated interference screen identifies miR-19 targets in Notchinduced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 2010; 12: 372-9.
58. de Antonellis P, Medaglia C, Cusanelli E, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumorpropagating cells and supports neural differentiation in medulloblastoma. PloS one 2011; 6: e24584.
59. Yang Y, Ahn YH, Gibbons DL, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 2011; 121: 1373-85.
60. Chen L, Zhang W, Yan W, et al. The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis 2012; 33: 2276-82.
61. Bae Y, Yang T, Zeng HC, et al. miRNA-34c regulates Notch signaling during bone development. Hum Mol Genet 2012; 21: 2991-3000.
62. Pang RT, Leung CO, Ye TM, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010; 31: 1037-44.
63. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-4.
64. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-307.
65. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-43.
66. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-9.
67. Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009; 69: 7569-76.
68. Guessous F, Zhang Y, Kofman A, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010; 9: 1031-6.
69. Ji X, Wang Z, Geamanu A, et al. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. International journal of cancer. Int J Cancer 2012; 131: 2668-77.
70. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC cancer 2008; 8: 266.
71. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS one 2009; 4: e6816.
72. Maire G, Martin JW, Yoshimoto M, et al. Analysis of miRNAgene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 2011; 204: 138-46.
73. Yan K, Gao J, Yang T, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PloS one 2012; 7: e33778.
74. Ohashi S, Natsuizaka M, Naganuma S, et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMTcompetent cells that express the ZEB transcription factors. Cancer Res 2011; 71: 6836-47.
75. Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 2009; 284: 31921-7.
76. Ghisi M, Corradin A, Basso K, et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 2011; 117: 7053-62.
77. Hashimoto Y, Akiyama Y, Otsubo T, Shimada S, Yuasa Y. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis 2010; 31: 777-84.
78. Sureban SM, May R, Lightfoot SA, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011; 71: 2328-38.
79. Yu F, Jiao Y, Zhu Y, et al. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelialmesenchymal transition in breast tumor-initiating cells. J Biol Chem 2012; 287: 465-73.
80. Hughes DP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 2009; 152: 479-96.
81. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PloS one 2009; 4: e4998.
82. Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cellular and molecular life sciences: CMLS 2009; 66: 1631-46.
83. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelialmesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011; 307: 26-36.
84. Gusscott S, Kuchenbauer F, Humphries RK, Weng AP. Notchmediated repression of miR-223 contributes to IGF1R regulation in T-ALL. Leuk Res 2012; 36: 905-11.
85. Hamidi H, Gustafason D, Pellegrini M, Gasson J. Identification of novel targets of CSL-dependent Notch signaling in hematopoiesis. PloS one 2011; 6: e20022.
86. Thatcher EJ, Flynt AS, Li N, Patton JR, Patton JG. MiRNA expression analysis during normal zebrafish development and following inhibition of the Hedgehog and Notch signaling pathways. Dev Dyn 2007; 236: 2172-80.
87. Kefas B, Comeau L, Floyd D H, et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci 2009; 29: 15161-8.
88. Malaney S, Daly R J. The ras signaling pathway in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 101-13.
89. Gohring UJ, Schondorf T, Kiecker VR, et al. Immunohistochemical detection of H-ras protooncoprotein p21 indicates favorable prognosis in node-negative breast cancer patients. Tumour Biol 1999; 20: 173-83.
90. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002; 8: 979-86.
91. Johnson S M, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-47.
92. Wang Z, Banerjee S, Ahmad A, et al. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-kappaB signaling pathways. PloS one 2011; 6: e20537.
93. Kashat M, Azzouz L, Sarkar SH, et al. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 2012; 4: 432-42.
94. Ayyanan A, Civenni G, Ciarloni L, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA 2006; 103: 3799-804.
95. Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 2003; 278: 32227-35.
96. Uyttendaele H, Soriano JV, Montesano R, Kitajewski J. Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. Dev Biol 1998; 196: 204-17.
97. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11: 860-72.
98. O'Loughlin AJ, Woffindale CA, Wood MJ. Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Therapy 2012; 12: 262-74.
99. Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120.
100. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-59.
101. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PloS one 2011; 6: e24099.
102. Sureban SM, May R, Mondalek FG, et al. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology 2011; 9: 40.
103. Wang Z, Li Y, Ahmad A, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010; 1806: 258-67.
104. Xia J, Duan Q, Ahmad A, et al. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets 2012.
105. Roy S, Levi E, Majumdar AP, Sarkar FH. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol 2012; 5: 58.
106. Bao B, Ali S, Banerjee S, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012; 72: 335-45.
107. Vlachos I S, Kostoulas N, Vergoulis T, et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012; 40: W498-W504.